These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 18811599)

  • 1. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
    Zinner N; Kobashi KC; Ebinger U; Viegas A; Egermark M; Quebe-Fehling E; Koochaki P
    Int J Clin Pract; 2008 Nov; 62(11):1664-74. PubMed ID: 18811599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
    Zinner N; Kobashi K; Koochaki P; Fix D; Egermark M
    Neurourol Urodyn; 2011 Jan; 30(1):62-8. PubMed ID: 20860020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
    Hill S; Elhilali M; Millard RJ; Dwyer PL; Lheritier K; Kawakami FT; Steel M
    Curr Med Res Opin; 2007 Nov; 23(11):2697-704. PubMed ID: 17892634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
    Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Guan Z; Choo MS
    Int J Clin Pract; 2009 Apr; 63(4):560-7. PubMed ID: 19348029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.
    Chancellor MB; Kianifard F; Beamer E; Mongay L; Ebinger U; Hicks G; Delconte A
    Int J Clin Pract; 2008 Apr; 62(4):606-13. PubMed ID: 18324952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.